title: Use of liver grafts from anti-hepatitis B core-positive donors: a multicenter study in Argentina.
abstract: Liver transplantation success is limited by the availability of donors. To overcome this limitation, anti-core-positive donors are increasingly being accepted, but underutilization of this resource still occurs. We performed the current study to determine the prevalence of anti-core-positive donors in our region and to describe the management of these donors and their recipients. Between January 2005 and July 2011, the national transplant database included 2,262 registered liver donors among whom 106 (4.7%) were anti-core-positive including 59 (56%) discarded and 47 (44%) implanted organs. A median of 14.5 offers (range 4-60) were rejected before harvesting and implanting the accepted grafts. The only difference between the implanted and the discarded grafts was found for the alanine aminotransferase level, which was higher among the discarded ones (50 ± 59 UI/L vs 25 ± 16, P < .05). Among 40 recipients included in the study, 5 (12.5%) did not receive any prophylaxis; 18 (45%) a nucleos(t)ide analog 11 (25.5%), heptitis B immunoglobulin and nucleos(t)ide analogs and 6 (15%) pretransplant hepatitis B vaccination. Over a mean follow-up of 871 ± 585 days, 4 de novo hepatitis B cases were identified at 545, 720, 748, and 1,080 days posttransplantation. None of these patients had received any prophylaxis. In all cases entecavir successfully controlled viral replication. We believe that better utilization of these donors and careful management of their recipients represent safe strategies to expand the liver donor pool in Argentina.
authors.affiliation: Hepatology Unit, Hospital Italiano de Buenos Aires, Argentina. sebastian.marciano@hospitalitaliano.org.ar
authors.forename: S
authors.initials: S
authors.lastname: Marciano
authors.forename: L A
authors.initials: LA
authors.lastname: Gaite
authors.forename: L
authors.initials: L
authors.lastname: Bisignano
authors.forename: V I
authors.initials: VI
authors.lastname: Descalzi
authors.forename: S
authors.initials: S
authors.lastname: Yantorno
authors.forename: M
authors.initials: M
authors.lastname: Mendizabal
authors.forename: M O
authors.initials: MO
authors.lastname: Silva
authors.forename: M
authors.initials: M
authors.lastname: Anders
authors.forename: O F
authors.initials: OF
authors.lastname: Orozco
authors.forename: R
authors.initials: R
authors.lastname: Traverso
authors.forename: O
authors.initials: O
authors.lastname: Gil
authors.forename: O A
authors.initials: OA
authors.lastname: Galdame
authors.forename: J C
authors.initials: JC
authors.lastname: Bandi
authors.forename: E
authors.initials: E
authors.lastname: de Santibañes
authors.forename: A C
authors.initials: AC
authors.lastname: Gadano
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D001118:Argentina; D005260:Female; D006085:Graft Survival; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D006801:Humans; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D014019:Tissue Donors
chemical_list: D006514:Hepatitis B Surface Antigens; D000410:Alanine Transaminase